Examkin

Soru

Zorluk: KolayMonitoring and Treatment Evaluation

A 68-year-old man comes to the clinic for routine monitoring of his anticoagulation therapy. He has a history of nonvalvular atrial fibrillation and has been taking warfarin for the past 2 years with a stable target International Normalized Ratio (INR) between 2.0 and 3.0. Last week, he was prescribed a 7-day course of trimethoprim-sulfamethoxazole for an uncomplicated urinary tract infection. The patient reports feeling well and denies any bruising, hematuria, melena, or other signs of bleeding. His vital signs are within normal limits. Today, his laboratory results show an INR of 5.4. Which of the following is the most appropriate next step in the management of this patient?

  1. Omit the next 1 to 2 doses of warfarin and recheck the INR in 1 to 2 daysCevap
  2. B
    Administer oral vitamin K and decrease the weekly warfarin dose
  3. C
    Administer intravenous vitamin K and fresh frozen plasma
  4. D
    Continue the current warfarin dose and recheck the INR in 1 week
  5. E
    Discontinue warfarin and immediately initiate an oral direct thrombin inhibitor

Cevap

Omit the next 1 to 2 doses of warfarin and recheck the INR in 1 to 2 days
The correct approach for a patient with an INR between 4.5 and 10.0 and no evidence of bleeding is to omit the next 1 to 2 doses of warfarin, monitor the INR closely, and resume therapy at an appropriately adjusted dose once the INR falls back into the therapeutic range. This patient's supratherapeutic INR is a direct result of a pharmacokinetic drug-drug interaction with trimethoprim-sulfamethoxazole, a well-known inhibitor of CYP2C9. Because the patient is entirely asymptomatic and hemodynamically stable, conservative management with dose withholding is the safest and most effective standard of care.

Adım Adım Çözüm

1
Evaluate the patient's clinical presentation and laboratory data.
The patient has an elevated INR of 5.4 but is entirely asymptomatic with no evidence of active bleeding.
Bleeding status dictates whether rapid reversal (with Vitamin K, FFP, or PCC) or conservative management is indicated.
2
Identify the etiology of the supratherapeutic INR.
The recent initiation of trimethoprim-sulfamethoxazole caused a drug-drug interaction, as it inhibits the cytochrome P450 2C9 enzyme, thereby decreasing warfarin metabolism.
Understanding the underlying cause helps in adjusting future doses and preventing recurrence.
3
Determine the guideline-directed management for the specific INR range.
For an INR between 4.5 and 10.0 without clinically significant bleeding, the recommended management is to simply omit the next 1 to 2 doses of warfarin and closely monitor the INR.
Conservative management avoids the risk of warfarin resistance that can occur with unnecessary vitamin K administration.

Anahtar Kavram

Management of supratherapeutic INR without bleeding
Bu soruyu puanla

Konular

Monitoring and Treatment Evaluation

Bu konudan daha fazla soru